News

New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites

18 March 2024

Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.

Student wins award for Individual Excellence in Clinical Data Management

7 March 2024

Yama Mujadidi, DPhil student and Clinical Trials IT & Development Lead at the Oxford Vaccine Group, has been awarded the prize for Individual Excellence by the Association for Clinical Data Management.

MDUK Oxford Neuromuscular Centre celebrates five year anniversary

31 January 2024

The Department of Paediatrics at the University of Oxford is celebrating the five-year anniversary of a partnership with MDUK. Founded in January 2019, the MDUK Oxford Neuromuscular Centre was set up to drive the development of new therapies and treatments and increase the capacity of clinical trials for muscle wasting and weakening conditions in the UK.

First in-human vaccine trial for Nipah virus

11 January 2024

The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.

New campaign by Oxford Vaccine Group hopes to boost jab numbers

8 December 2023

Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.

Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines

25 October 2023

A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.

First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)

18 September 2023

Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).

First in-human trials commence for CCHF vaccine

12 September 2023

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

New study to test babies for Spinal Muscular Atrophy

30 August 2023

Scientists at the University of Oxford are running a study at participating hospitals in the Thames Valley and Wessex regions, offering parents the ability to have their newborn baby’s blood tested for Spinal Muscular Atrophy (SMA), in addition to the nine other conditions that are already tested for.

Phase I trial begins of new vaccine against the Plague

27 July 2021

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Mockup of two doses of a COVID-19 vaccine with needle

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

30 June 2021

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

28 June 2021

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

28 June 2021

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Alternating vaccines trial expands to include two additional vaccines

14 April 2021

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford leads first trial investigating dosing with alternating vaccines

4 February 2021

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

15 June 2020

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.